Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles2 certified filings for “Director, Brand Analytics” (Data Scientists) in DE: $205k–$225k, median $215k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles
- 2 certified filings for “Director, Brand Analytics” (Data Scientists) in DE: $205k–$225k, median $215k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
PanKRAS represents one of the most exciting growth opportunities within AstraZeneca’s GI Oncology portfolio and is expected to play a pivotal role in our ambition to lead in Pancreatic, Colorectal, and Lung cancer. As Senior Director, Global Commercial, panKRAS, you will lead the global commercial strategy for AstraZeneca’s panKRAS asset, a clinical stage, oral, multi-target KRAS inhibitor, with the potential to transform outcomes for patients across multiple tumor settings where KRAS is considered to be a relevant clinical target.
Given the asset’s earlier stage of development, you will shape its commercial potential from the outset by providing strategic and commercial input to development priorities, evidence generation and key investment decisions. You will translate patient, customer, market and competitive insights into clear choices on target indications, patient populations, target product profile, differentiation and sequencing, while building the foundation for future launch excellence and leading commercial preparation for the panKRAS lead indication.
Job description
The Senior Director, Global Commercial, panKRAS will be part of the Global IO Commercial Franchise Team and will set and implement the global commercial strategy for this priority asset. Reflecting the asset’s earlier stage of development, the role will provide proactive commercial and strategic input to development priorities and decisions, working closely with Clinical Development, Global Medical Affairs, Regulatory Affairs, Diagnostics, Pricing and Market Access, Global Analytics & Insights, Digital, Corporate Affairs, regional and country teams, and other partners. The role will ensure that patient, customer, market and competitive insights inform indication prioritisation, target product profile, evidence-generation strategy, investment choices and the pathway to launch.
The role is accountable for creating a differentiated strategy and positioning, generating deep customer and market insights, supporting and informing development priorities and investment decisions for the clinical and evidence programme, delivering market-shaping programmes to maximise patient and business impact, and conducting commercial planning and preparations through to launch and beyond. It also represents Global Commercial perspectives in relevant cross-functional team and governance forums, ensuring development choices are grounded in future patient, customer and market needs.
Typical accountabilities | Job responsibilities
1. Global brand strategy and leadership
· Set and communicate a clear, differentiated and long-term global brand strategy for our panKRAS asset, aligned with the GI tumour strategy and broader Oncology priorities.
· Lead annual strategic and operational planning, including positioning, segmentation, customer strategy, value proposition, target market selection and lifecycle priorities.
· Generate deep customer, patient, market and competitive insights and translate them into choices that address unmet need and maximise value.
· Provide proactive commercial and strategic input to development priorities and decisions, including indication and patient-segment prioritisation, target product profile, evidence-generation needs, clinical development trade-offs and key investment choices.
· Develop future-focused revenue forecasts and business cases informed by robust insights and sound commercial judgement.
· Represent Global Commercial in relevant Global Product Team, development and investment decision forums, providing commercially rigorous input to evidence generation, clinical development strategy, stage-gate decisions and Phase III investment choices.
2. Launch excellence and market shaping
· Lead global launch strategy, launc
Apply on employer site ↗